154 related articles for article (PubMed ID: 38664571)
21. Facioscapulohumeral dystrophy in children: design of a prospective, observational study on natural history, predictors and clinical impact (iFocus FSHD).
Goselink RJ; Schreuder TH; Mul K; Voermans NC; Pelsma M; de Groot IJ; van Alfen N; Franck B; Theelen T; Lemmers RJ; Mah JK; van der Maarel SM; van Engelen BG; Erasmus CE
BMC Neurol; 2016 Aug; 16():138. PubMed ID: 27530735
[TBL] [Abstract][Full Text] [Related]
22. Facioscapulohumeral muscular dystrophy 1 patients participating in the UK FSHD registry can be subdivided into 4 patterns of self-reported symptoms.
Banerji CRS; Cammish P; Evangelista T; Zammit PS; Straub V; Marini-Bettolo C
Neuromuscul Disord; 2020 Apr; 30(4):315-328. PubMed ID: 32327287
[TBL] [Abstract][Full Text] [Related]
23. Clinical expression of facioscapulohumeral muscular dystrophy in carriers of 1-3 D4Z4 reduced alleles: experience of the FSHD Italian National Registry.
Nikolic A; Ricci G; Sera F; Bucci E; Govi M; Mele F; Rossi M; Ruggiero L; Vercelli L; Ravaglia S; Brisca G; Fiorillo C; Villa L; Maggi L; Cao M; D'Amico MC; Siciliano G; Antonini G; Santoro L; Mongini T; Moggio M; Morandi L; Pegoraro E; Angelini C; Di Muzio A; Rodolico C; Tomelleri G; Grazia D'Angelo M; Bruno C; Berardinelli A; Tupler R
BMJ Open; 2016 Jan; 6(1):e007798. PubMed ID: 26733561
[TBL] [Abstract][Full Text] [Related]
24. A complex interplay of genetic and epigenetic events leads to abnormal expression of the DUX4 gene in facioscapulohumeral muscular dystrophy.
Gatica LV; Rosa AL
Neuromuscul Disord; 2016 Dec; 26(12):844-852. PubMed ID: 27816329
[TBL] [Abstract][Full Text] [Related]
25. Transgenic mice expressing tunable levels of DUX4 develop characteristic facioscapulohumeral muscular dystrophy-like pathophysiology ranging in severity.
Jones TI; Chew GL; Barraza-Flores P; Schreier S; Ramirez M; Wuebbles RD; Burkin DJ; Bradley RK; Jones PL
Skelet Muscle; 2020 Apr; 10(1):8. PubMed ID: 32278354
[TBL] [Abstract][Full Text] [Related]
26. Early onset facioscapulohumeral dystrophy - a systematic review using individual patient data.
Goselink RJM; Voermans NC; Okkersen K; Brouwer OF; Padberg GW; Nikolic A; Tupler R; Dorobek M; Mah JK; van Engelen BGM; Schreuder THA; Erasmus CE
Neuromuscul Disord; 2017 Dec; 27(12):1077-1083. PubMed ID: 29102079
[TBL] [Abstract][Full Text] [Related]
27. Facioscapulohumeral Muscular Dystrophy.
Statland JM; Tawil R
Continuum (Minneap Minn); 2016 Dec; 22(6, Muscle and Neuromuscular Junction Disorders):1916-1931. PubMed ID: 27922500
[TBL] [Abstract][Full Text] [Related]
28. Facioscapulohumeral Muscular Dystrophy European Patient Survey: Assessing Patient Reported Disease Burden and Preferences in Clinical Trial Participation.
McNiff MM; Hawkins S; Haase B; Bullivant J; McIver T; Mitelman O; Emery N; Tasca G; Voermans N; Diaz-Manera J
J Neuromuscul Dis; 2024; 11(2):459-472. PubMed ID: 38277300
[TBL] [Abstract][Full Text] [Related]
29. Large-scale population analysis challenges the current criteria for the molecular diagnosis of fascioscapulohumeral muscular dystrophy.
Scionti I; Greco F; Ricci G; Govi M; Arashiro P; Vercelli L; Berardinelli A; Angelini C; Antonini G; Cao M; Di Muzio A; Moggio M; Morandi L; Ricci E; Rodolico C; Ruggiero L; Santoro L; Siciliano G; Tomelleri G; Trevisan CP; Galluzzi G; Wright W; Zatz M; Tupler R
Am J Hum Genet; 2012 Apr; 90(4):628-35. PubMed ID: 22482803
[TBL] [Abstract][Full Text] [Related]
30. Single-molecule optical mapping enables quantitative measurement of D4Z4 repeats in facioscapulohumeral muscular dystrophy (FSHD).
Dai Y; Li P; Wang Z; Liang F; Yang F; Fang L; Huang Y; Huang S; Zhou J; Wang D; Cui L; Wang K
J Med Genet; 2020 Feb; 57(2):109-120. PubMed ID: 31506324
[TBL] [Abstract][Full Text] [Related]
31. Correlation between whole body muscle MRI and functional measures in paediatric patients with facioscapulohumeral muscular dystrophy.
Woodcock IR; de Valle K; Varma N; Kean M; Ryan MM
Neuromuscul Disord; 2023 Jan; 33(1):15-23. PubMed ID: 36522253
[TBL] [Abstract][Full Text] [Related]
32. Facioscapulohumeral muscular dystrophy family studies of DUX4 expression: evidence for disease modifiers and a quantitative model of pathogenesis.
Jones TI; Chen JC; Rahimov F; Homma S; Arashiro P; Beermann ML; King OD; Miller JB; Kunkel LM; Emerson CP; Wagner KR; Jones PL
Hum Mol Genet; 2012 Oct; 21(20):4419-30. PubMed ID: 22798623
[TBL] [Abstract][Full Text] [Related]
33. Sporadic DUX4 expression in FSHD myocytes is associated with incomplete repression by the PRC2 complex and gain of H3K9 acetylation on the contracted D4Z4 allele.
Haynes P; Bomsztyk K; Miller DG
Epigenetics Chromatin; 2018 Aug; 11(1):47. PubMed ID: 30122154
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic approach for FSHD revisited: SMCHD1 mutations cause FSHD2 and act as modifiers of disease severity in FSHD1.
Larsen M; Rost S; El Hajj N; Ferbert A; Deschauer M; Walter MC; Schoser B; Tacik P; Kress W; Müller CR
Eur J Hum Genet; 2015 Jun; 23(6):808-16. PubMed ID: 25370034
[TBL] [Abstract][Full Text] [Related]
35. A Human Pluripotent Stem Cell Model of Facioscapulohumeral Muscular Dystrophy-Affected Skeletal Muscles.
Caron L; Kher D; Lee KL; McKernan R; Dumevska B; Hidalgo A; Li J; Yang H; Main H; Ferri G; Petek LM; Poellinger L; Miller DG; Gabellini D; Schmidt U
Stem Cells Transl Med; 2016 Sep; 5(9):1145-61. PubMed ID: 27217344
[TBL] [Abstract][Full Text] [Related]
36. Simultaneous measurement of the size and methylation of chromosome 4qA-D4Z4 repeats in facioscapulohumeral muscular dystrophy by long-read sequencing.
Hiramuki Y; Kure Y; Saito Y; Ogawa M; Ishikawa K; Mori-Yoshimura M; Oya Y; Takahashi Y; Kim DS; Arai N; Mori C; Matsumura T; Hamano T; Nakamura K; Ikezoe K; Hayashi S; Goto Y; Noguchi S; Nishino I
J Transl Med; 2022 Nov; 20(1):517. PubMed ID: 36348371
[TBL] [Abstract][Full Text] [Related]
37. Characterization of D4Z4 alleles and assessment of de novo cases in Facioscapulohumeral dystrophy (FSHD) in a cohort of Italian families.
Strafella C; Colantoni L; Megalizzi D; Trastulli G; Piorgo EP; Primiano G; Sancricca C; Ricci G; Siciliano G; Caltagirone C; Filosto M; Tasca G; Ricci E; Cascella R; Giardina E
Clin Genet; 2024 Mar; 105(3):335-339. PubMed ID: 38041579
[TBL] [Abstract][Full Text] [Related]
38. [Characteristics of gene structure in facioscapulohumeral muscular dystrophy-related 4q35 subtelomere and genotype-phenotype correlation in Chinese Han population].
Wang ZQ; Wu ZY; Wang N; Lin MT; Murong SX
Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(5):304-9. PubMed ID: 19563705
[TBL] [Abstract][Full Text] [Related]
39. Optical Genome Mapping for the Molecular Diagnosis of Facioscapulohumeral Muscular Dystrophy: Advancement and Challenges.
Efthymiou S; Lemmers RJLF; Vishnu VY; Dominik N; Perrone B; Facchini S; Vegezzi E; Ravaglia S; Wilson L; van der Vliet PJ; Mishra R; Reyaz A; Ahmad T; Bhatia R; Polke JM; Srivastava MP; Cortese A; Houlden H; van der Maarel SM; Hanna MG; Bugiardini E
Biomolecules; 2023 Oct; 13(11):. PubMed ID: 38002249
[TBL] [Abstract][Full Text] [Related]
40. Muscle fibrosis as a prognostic biomarker in facioscapulohumeral muscular dystrophy: a retrospective cohort study.
Ragozzino E; Bortolani S; Di Pietro L; Papait A; Parolini O; Monforte M; Tasca G; Ricci E
Acta Neuropathol Commun; 2023 Oct; 11(1):165. PubMed ID: 37849014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
